Rachel McMinn - 22 Nov 2024 Form 4 Insider Report for Neurogene Inc. (NGNE)

Role: Chief Executive Officer, Director
Signature: /s/ Christine Mikail, as attorney-in-fact for Rachel McMinn
Issuer symbol: NGNE
Transactions as of: 22 Nov 2024
Net transactions value: +$969,000
Form type: 4
Filing time: 25 Nov 2024, 21:29:04 UTC
Previous filing: 14 Mar 2024
Next filing: 28 Mar 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NGNE	Common Stock	Purchase	$969,000	+47,500	+3.8%	$20.40	1,297,859	22 Nov 2024	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.07 to $20.84, inclusive. The reporting person undertakes to provide to Neurogene Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Content

The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.07 to $20.84, inclusive. The reporting person undertakes to provide to Neurogene Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.